New immune cell therapy tested for aggressive brain tumors
NCT ID NCT04214392
Summary
This is an early-stage safety study for a new type of CAR T-cell therapy designed for adults with a specific type of recurrent brain cancer called glioblastoma. The main goals are to find the safest dose and understand the side effects. Doctors will collect a patient's own immune cells, modify them in a lab to better target the tumor, and then infuse them back into the brain.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.